NIH-funded research R01 grant

Understanding how food allergens cause severe allergic reactions

Official title: Determinants of oral anaphylaxis to food

Funded at Northwestern University at Chicago · NIH-10923786 · Data updated 2026-11-12

This study is looking at how food allergens, like peanuts and eggs, can get through the gut barrier and cause serious allergic reactions in kids, and it aims to find out if certain genes and new treatments can help protect against this.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionNorthwestern University at Chicago
NIH-funded
Lab location1 site (Chicago, United States)
Project startSeptember 7, 2023
Project endAugust 31, 2027
Funding year2024
Award (this year)$798,975
NIH project number5R01AI168016-02
Project IDNIH-10923786 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are children aged 0-11 years who have been diagnosed with food allergies, particularly to peanuts or eggs.

Less likely to help

Patients who do not have food allergies or are older than 11 years may not benefit from this research.

What this research studies

This research aims to uncover the cellular and molecular mechanisms that allow food allergens to cross the gut barrier, which can lead to life-threatening anaphylaxis in children with food allergies. By studying mouse models of peanut and egg allergies, the researchers will explore genetic factors that influence the risk of anaphylaxis and investigate potential drug treatments that could strengthen the gut barrier. The study will involve advanced genetic mapping techniques to identify specific genes associated with reduced gut permeability to allergens.

Why it matters

Potential benefit: If successful, this research could lead to new prevention strategies for food allergies, potentially reducing the incidence of anaphylaxis in affected children.

How similar studies have gone: Previous research has shown promise in understanding genetic factors related to food allergies, but this specific approach using genetic mapping and drug treatments is relatively novel.

Where this research is happening

  • Northwestern University at Chicago
    Chicago, United States
    Active

Researchers

  • Principal investigator: Williams, Adam — Northwestern University at Chicago
  • Study coordinator: Williams, Adam

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.